Gyre Therapeutics (GYRE) has issued an announcement.
Gyre Therapeutics has announced the approval of its IND application by China’s CDE for F230 tablets, aimed at treating pulmonary arterial hypertension. This milestone indicates the potential for F230 to address PAH, with additional disease indications being explored. While the announcement is promising, the company notes that these forward-looking statements are subject to significant risks and uncertainties, and actual outcomes may differ from current expectations.
For a thorough assessment of GYRE stock, go to TipRanks’ Stock Analysis page.